IPCALAB2021-04-012021-06-30in-bse-fin:OneOperatingExpenses01Member IPCALAB2021-04-012021-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IPCALAB2021-04-012021-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member IPCALAB2021-04-012021-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares IPCALAB 2021-04-01 2022-03-31 2021-07-22 INR Crores First quarter Single segment Pharmaceuticals 2021-04-01 2021-06-30 Unaudited Consolidated 15657900000.00 210200000.00 15868100000.00 4132300000.00 966200000.00 358500000.00 2996000000.00 18200000.00 558700000.00 3039500000.00 12069400000.00 3798700000.00 0.00 3798700000.00 644800000.00 62900000.00 707700000.00 0.00 3091000000.00 0.00 0.00 0.00 -24300000.00 3066700000.00 30500000.00 3097200000.00 3066600000.00 100000.00 3096300000.00 900000.00 253700000.00 2 24.18 24.18 0.00 0.00 24.18 24.18 Notes: 1 The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 5, 2021 The Statutory Auditors have carried out the limited review of the results. 2 During the quarter, the Company has acquired further 13.09% of the paid-up equity share capital of M/s. Trophic Wellness Private Ltd. (TWPL), a company engaged in the business of manufacturing and marketing of Neutraceuticals. With this acquisition, TWPL has now become a subsidiary of the Company. The Company now holds 52.35% of the paid-up equity share capital of TWPL. 3 The Group has only one operating segment viz. 'Pharmaceuticals'. 4 *The figures for the quarter ended March 31, 2021 are the balancing figures between audited figures in respect of the full financial year 2020-21 and the published year to date unaudited figures upto December 31,2020. 5 Figures for the previous periods have been regrouped / re-classified to conform to the figures of the current period. Other expenses 3039500000.00